PUBLISHER: The Business Research Company | PRODUCT CODE: 1947134
PUBLISHER: The Business Research Company | PRODUCT CODE: 1947134
Single-photon emission computed tomography (SPECT) is a medical imaging technique that utilizes radioactive tracers and gamma rays to generate three-dimensional images of internal organs and tissues. The gamma camera detects the emitted gamma rays from the tracer, enabling non-invasive and detailed imaging of a patient's internal structure.
The primary categories of single-photon emission computed tomography (SPECT) systems are hybrid and standalone SPECT systems. Hybrid SPECT systems refer to medical imaging devices that integrate functional and anatomical information obtained from SPECT with CT or MRI, facilitating more precise diagnoses. Various radioisotopes are involved in SPECT systems, including Tc-99m, Ra-223, Ga-67, I-123, and other radioisotopes. These find applications in various fields such as oncology, cardiology, neurology, and are utilized by hospitals, diagnostic centers, and other end-users.
Tariffs are impacting the SPECT market by increasing costs of imported gamma cameras, detectors, collimators, electronic imaging components, and specialized radioisotope handling equipment. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported high-end imaging systems, while Asia-Pacific faces higher equipment acquisition costs. These tariffs are increasing capital expenditure and delaying system upgrades. However, they are also encouraging regional manufacturing, localized system assembly, and domestic servicing capabilities for nuclear imaging equipment.
The single-photon emission computed tomography (spect) market research report is one of a series of new reports from The Business Research Company that provides single-photon emission computed tomography (spect) market statistics, including single-photon emission computed tomography (spect) industry global market size, regional shares, competitors with a single-photon emission computed tomography (spect) market share, detailed single-photon emission computed tomography (spect) market segments, market trends and opportunities, and any further data you may need to thrive in the single-photon emission computed tomography (spect) industry. This single-photon emission computed tomography (spect) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The single-photon emission computed tomography (spect) market size has grown strongly in recent years. It will grow from $2.5 billion in 2025 to $2.73 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to expansion of nuclear medicine applications, growth in diagnostic imaging procedures, increasing prevalence of cardiovascular and neurological disorders, rising hospital investments in imaging infrastructure, adoption of radioisotope-based diagnostics.
The single-photon emission computed tomography (spect) market size is expected to see strong growth in the next few years. It will grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing demand for advanced molecular imaging, rising adoption of precision diagnostics, expansion of outpatient diagnostic centers, growing integration of AI in medical imaging, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of hybrid spect imaging systems, rising use of ai-assisted image reconstruction, growing demand for cardiac and oncology imaging, expansion of multi-head gamma camera systems, enhanced focus on diagnostic accuracy.
The increasing prevalence of cancer cases is anticipated to drive the growth of the single-photon emission computed tomography (SPECT) market in the coming years. The growing incidence of cancer is largely attributed to an expanding aging population, unhealthy lifestyle habits, and adverse environmental conditions. Single-photon emission computed tomography (SPECT) plays a vital role in the diagnosis, staging, and ongoing monitoring of cancer, often used alongside other imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI). For example, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, approximately 41 million deaths occurred globally each year due to non-communicable or chronic diseases, accounting for 74% of total deaths. These included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. As a result, the rising burden of cancer is contributing to the expansion of the single-photon emission computed tomography (SPECT) market.
Major companies operating in the single-photon emission computed tomography (SPECT) space are focusing on the development of innovative solutions, such as portable gamma cameras, to enhance revenue generation. Clinical evaluations of portable gamma cameras reflect technological progress aimed at improving the accessibility, flexibility, and broader clinical application of SPECT imaging across diverse healthcare settings. For instance, in June 2023, Serac Imaging, a United Kingdom-based molecular imaging company, introduced a portable high-resolution hybrid gamma optical camera. The device is designed to complement existing technologies used in nuclear medicine departments, with the objective of simplifying clinical workflows and adding incremental imaging capacity.
In April 2025, GE HealthCare Technologies, Inc., a United States-based diagnostics company, acquired the remaining 50% equity stake in Nihon Medi-Physics Co., Ltd. from Sumitomo Chemical for an undisclosed consideration. Through this transaction, GE HealthCare sought to obtain full ownership of a leading Japanese radiopharmaceutical company in order to further expand its molecular imaging operations, strengthen its therapeutic diagnostics portfolio, and enhance its footprint in the expanding nuclear medicine sector. Nihon Medi-Physics Co., Ltd. is a Japan-based pharmaceutical diagnostics company engaged in the development and manufacturing of proprietary and in-licensed radiopharmaceuticals used in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging.
Major companies operating in the single-photon emission computed tomography (spect) market are GE Healthcare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Canon Medical Systems Corporation, United Imaging Healthcare Co. Ltd., Mediso Ltd., Spectrum Dynamics Medical Inc., Digirad Corporation, Gamma Medica Inc., Neusoft Medical Systems Co. Ltd., Trasis S.A., Curium Pharma, Lantheus Holdings Inc., Bracco Imaging S.p.A., Guerbet S.A., Eckert & Ziegler AG, Nordion Inc., Bayer AG, Advanced Accelerator Applications, Ion Beam Applications S.A., Hitachi Ltd.
North America was the largest region in the single-photon emission computed tomography (SPECT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the single-photon emission computed tomography (SPECT) market report during the forecast period. The regions covered in the single-photon emission computed tomography (spect) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the single-photon emission computed tomography (spect) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The single-photon emission computed tomography (SPECT) market consists of the sale of SPECT/CT and of Single Imaging Gamma Cameras. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Single-Photon Emission Computed Tomography (SPECT) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses single-photon emission computed tomography (spect) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for single-photon emission computed tomography (spect) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The single-photon emission computed tomography (spect) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.